References
- Dulucq S, Krajinovic M. The pharmacogenetics of imanitib. Genome Med 2010;2:85. https://doi.org/10.1186/gm206
- Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56. https://doi.org/10.1016/j.joms.2014.04.031
- Lutz JC, El-Bouihi M, Vidal N, Fricain JC, Robert M, Deminiere C, et al. Mandibular metastases from an ileum stromal tumor. Rev Stomatol Chir Maxillofac 2008;109:399-402. https://doi.org/10.1016/j.stomax.2008.09.010
- Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-6. https://doi.org/10.1056/NEJM200104053441404
- Yeh CN, Fu CJ, Yen TC, Chiang KC, Jan YY, Chen MF. Osteonecrosis of the tibia associated with imatinib in metastatic GI stromal tumor. J Clin Oncol 2013;31:e248-50. https://doi.org/10.1200/JCO.2012.45.1294
- Nicolatou-Galitis O, Razis E, Galiti D, Vardas E, Tzerbos F, Labropoulos S. Osteonecrosis of the jaw in a patient with chronic myelogenous leukemia receiving imatinib. A case report with clinical implications. Forum Clin Oncol 2013;4:29-33.
- Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 2012;107:1665-71. https://doi.org/10.1038/bjc.2012.385
- Fleissig Y, Regev E, Lehman H. Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol 2012;113:e1-3. https://doi.org/10.1016/S2212-4403(11)00652-3
- Abramson RG, Abramson VG, Chan E, Horn L, Keedy VL, Pao W, et al. Complications of targeted drug therapies for solid malignancies: manifestations and mechanisms. AJR Am J Roentgenol 2013;200:475-83. https://doi.org/10.2214/AJR.12.9049
- Vlahovic G, Rabbani ZN, Herndon JE 2nd, Dewhirst MW, Vujaskovic Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. Br J Cancer 2006;95:1013-9. https://doi.org/10.1038/sj.bjc.6603366
- Litz J, Krystal GW. Imatinib inhibits c-Kit-induced hypoxiainducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. Mol Cancer Ther 2006;5:1415-22.
- Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010;115:766-74. https://doi.org/10.1182/blood-2009-08-237404
Cited by
- Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature vol.2018, pp.None, 2017, https://doi.org/10.1155/2018/8071579
- Denosumab Related Osteonecrosis of Jaw: a Case Report vol.9, pp.4, 2018, https://doi.org/10.5037/jomr.2018.9405
- Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review vol.27, pp.2, 2017, https://doi.org/10.1007/s00520-018-4501-x
- Deciphering novel chemotherapy and its impact on dentistry vol.228, pp.6, 2017, https://doi.org/10.1038/s41415-020-1365-5
- Imatinib-induced bone oedema mimicking Type 1 complex regional pain syndrome vol.59, pp.6, 2017, https://doi.org/10.1093/rheumatology/kez503
- Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors vol.8, pp.1, 2017, https://doi.org/10.1038/s41413-020-0088-1
- Osteonecrosis of the jaw in an anti‐resorptive naïve patient taking trastuzumab and pertuzumab: case report vol.65, pp.4, 2017, https://doi.org/10.1111/adj.12723
- Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies vol.11, pp.11, 2017, https://doi.org/10.3390/app11114865
- Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates vol.44, pp.12, 2017, https://doi.org/10.1007/s40618-021-01634-0